In view of these findings and the spectrum of pathologies observed in anti-IgLON5 disease in an extended autopsy series, and keeping in mind that the disease as such is defined by (1) the presence of anti-IgLON5 antibodies in the CSF and/or serum, and (2) the presence of neurological symptoms reflecting a predominantly brainstem involvement, we propose adapting the original research criteria that defined the unique tauopathy associated with the disease [23] accordingly (Table 4), and to delete the diagnostic category “possible”. This evidence concerns the gene IGLON5 and glycogen storage disease VI.